|
Gender: Female
|
38
|
42%
|
|
Male
|
52
|
58%
|
|
Age at diagnostic, median (range):
|
62 years
|
(22–82)
|
|
Age at SBRT, median (range):
|
65 years
|
(23–84)
|
|
Primary sites: Digestive
|
63
|
70%
|
|
Lung
|
3
|
3.3%
|
|
Breast
|
8
|
8.9%
|
|
Melanoma
|
4
|
4.4%
|
|
Neuro-endocrine
|
3
|
3.3%
|
|
Sarcoma
|
3
|
3.3%
|
|
Other
|
6
|
6.7%
|
|
Adenocarcinoma Histology: Hepatic (n = 75)
|
61
|
81%
|
|
Lung (n = 15)
|
7
|
47%
|
|
Primary for Adenocarcinoma histology
|
68
| |
|
Colorectal
|
57
|
84%
|
|
Breast
|
8
|
12%
|
|
Gastric
|
1
|
1.5%
|
|
Lung
|
1
|
1.5%
|
|
Kidney
|
1
|
1.5%
|
|
Primary for squamous cell histology :
|
7
| |
|
Esophagus
|
5
|
71%
|
|
Lung
|
2
|
29%
|
|
Other histologies :
|
15
|
17%
|
|
Lesions : Lung
|
15
|
17%
|
|
Hepatic
|
75
|
83%
|
|
Number of lesions treated by patient :
| | |
|
1
|
64
|
71%
|
|
2
|
19
|
21%
|
|
3
|
4
|
4%
|
|
4
|
3
|
3%
|
|
Timing of Metastases:
| | |
|
At initial diagnostic
|
43
|
49%
|
|
Within one year
|
20
|
23%
|
|
More than 1 year
|
25
|
28%
|
|
Time from diagnosis of metastasis to SBRT treatment, median (range)
|
25.6 months
|
(1.2 – 93.6)
|
|
Previous local treatment :
| | |
|
Hepatic (n = 75)
|
53
|
71%
|
|
Lung (n = 15)
|
0
|
0%
|
|
Prior chemotherapy:
| |
91%
|
|
Hepatic lesions (n = 75)
|
70
|
93%
|
|
Lung lesions (n = 15)
|
12
|
92%
|
|
Prior progressive disease with Chemo:
| | |
|
No
|
67
|
82%
|
|
Yes
|
15
|
18%
|
|
More than 3 chemotherapy regimens before SBRT :
| |
26,6%
|
|
Hepatic lesions (n = 75)
|
21
|
28%
|
|
Lung lesions (n = 15)
|
3
|
20%
|
